Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-109220
Filing Date
2025-08-14
Accepted
2025-08-14 21:55:30
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 13571
  Complete submission text file 0000950170-25-109220.txt   15369
Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

EIN.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Subject) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92695 | Film No.: 251222274
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)